Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis - ScienceDirect
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - The Lancet
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis | Arthritis Research & Therapy | Full Text
Prediction of Response to Targeted Treatment in Rheumatoid Arthritis - Mayo Clinic Proceedings
Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis | Arthritis Research & Therapy | Full Text
Internet Scientific Publications
Výsledek obrázku pro rituximab mechanism of action | Rheumatoid arthritis diet, Osteoarthritis, Rheumatoid arthritis
Frontiers | The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions | Pharmacology
Rituximab (Anti-Human CD20 type I, Chimeric Antibody) | CD20 Inhibitor | MedChemExpress
![ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/71089af2-c3c6-4866-9f65-ae959ab22bf4/gr1_lrg.jpg "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20")
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20
Current perspective on rituximab in rheumatic diseases | DDDT
Rituximab: modes of action, remaining dispute and future perspective | Future Oncology
Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire | Annals of the Rheumatic Diseases
A review of the current use of rituximab in autoimmune diseases - ScienceDirect
Targeting CD20: Monoclonals of the future - ppt download
Rituximab for the treatment of rheumatoid arthritis: an update | DDDT
Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire | Annals of the Rheumatic Diseases
Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library
Rituximab mode of action: apoptosis and ADCC. Rituximab mediated... | Download Scientific Diagram
